Targeted Genetics presents advances in systemic gene delivery ...( on its own and in collaboration with E...)

on its own and in collaboration with Elan Corporation plc (NYSE: ELN). In July 1999, Targeted Genetics and Elan established a joint venture, Emerald Gene Systems, to develop advanced gene delivery technologies. The joint venture combines the company's expertise in vector development and manufacturing with Elan's leadership in novel drug delivery technologies. The addition of Elan's targeting technologies to delivery vehicles such as LPD may provide targeted, systemic approaches for the delivery of therapeutic genes.

"The promising clinical and pre-clinical data that we are generating in studies of both our DCC and LPD delivery platforms validate our plan to develop multiple gene delivery strategies," said H. Stewart Parker, President and Chief Executive Officer of Targeted Genetics. "We were the first company to bring adeno-associated virus (AAV) vectors into the clinic and we are leading the charge to develop a synthetic systemic gene delivery system. Our excellence in the development of both viral and synthetic gene delivery technologies reflects our robust capabilities in identifying and developing promising approaches for clinical and commercial applications. Our multiple gene delivery technologies will enable us to capitalize on the growing number of genes identified through genomic discovery efforts and to deliver the right gene to the right patient using the right vector."

Background on LPD
Targeted Genetics, in collaboration with Dr. Leaf Huang, Ph.D., Joseph Koslow Professor of Pharmaceutical Sciences at the University of Pittsburgh's School of Pharmacy, is developing a series of improved synthetic delivery systems based on various formulations of cationic lipids. In one of these systems, designated "LPD" for lipid-polycation-DNA, the DNA is condensed through the addition of a polycation to form small, degradation resistant cores encapsulated in a lipid shell. The resulting LPD formulation contains particles of defined s
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x229
Noonan/Russo Communications
2-Apr-2000

Page: 1 2 3 4
Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted therapy for lung cancer patients shows promise in extending lives
3. Targeted immunotherapy eradicates cancer in mice
4. Targeted radiation to liver tumors spares tissue, improves quality of life
5. Targeted Genetics presents data on arthritis gene therapy
6. Targeted genetics presents promising data from cystic fibrosis clinical trial
7. Targeted Genetics presents clinical data on E1A cancer gene therapy
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin